NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

AL類澱粉蛋白沉積症:市場分析,流行病學,市場預測 (2030年)

AL Amyloidosis - Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 966657
出版日期 按訂單生產 內容資訊 英文 200 Pages
商品交期: 10個工作天內
價格
AL類澱粉蛋白沉積症:市場分析,流行病學,市場預測 (2030年) AL Amyloidosis - Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 按訂單生產內容資訊: 英文 200 Pages
簡介

本報告提供全球主要7個國家──美國,歐洲主要5國 (EU5:法國·德國·義大利·西班牙·英國 ),日本──的AL (Amyloid light-chain) 類澱粉蛋白沉積症的疫情趨勢和今後的市場預測相關分析,彙整疾病概要和市場基本結構,目前治療方法與未滿足需求,患病人數趨勢預測,已上市/臨床實驗中的治療藥的簡介,全球整體/各國的市場規模 (過去3年·今後11年份),主要的推動及阻礙市場要素等資訊,為您概述為以下內容。

目錄

第1章 主要考察

第2章 AL類澱粉蛋白沉積症:摘要整理

第3章 AL類澱粉蛋白沉積症的競爭資訊分析

第4章 AL類澱粉蛋白沉積症:市場概要

  • 整體市場佔有率結構 (2017年)
  • 整體市場佔有率結構 (2030年)

第5章 AL類澱粉蛋白沉積症:疾病概要

  • 簡介
  • 徵兆與症狀
  • 病理生理學
  • 危險因素
  • 診斷標準

第6章 患者治療流程

第7章 AL類澱粉蛋白沉積症的流行病學和患者人口

  • 流行病學分析的要點
  • 假設和理論的根據:主要7個國家
  • 流行病學方案:主要7個國家
    • AL類澱粉蛋白沉積症:主要7個國家的流行病學方案 (2017年∼2030年)
  • 美國的疫情趨勢
    • 美國國內的AL類澱粉蛋白沉積症的流行病學方案 (2017年∼2030年)
  • 歐洲5個國家:各國疫情趨勢
    • 德國的疫情趨勢
    • 法國的疫情趨勢
    • 義大利的疫情趨勢
    • 西班牙的疫情趨勢
    • 英國的疫情趨勢
  • 日本的疫情趨勢

第8章 治療流程,目前治療·診療方法

  • AL類澱粉蛋白沉積症的治療·管理方法
  • AL類澱粉蛋白沉積症的治療流程

第9章 未滿足需求

第10章 AL類澱粉蛋白沉積症治療的主要端點

第11章 已上市產品

  • 主要7個國家所販售的產品清單
  • 藥名:企業名
    • 產品說明
    • 法規的里程碑
    • 其他開發活動
    • 重要的臨床實驗:概要

第12章 新治療藥

  • 主要產品一覽
  • 藥名:企業名
    • 產品說明
    • 其他開發活動
    • 臨床開發
    • 安全性和有效性
    • 產品簡介

第13章 AL類澱粉蛋白沉積症:主要7個國家的市場分析

  • 分析主要的要點
  • AL類澱粉蛋白沉積症的市場規模:主要7個國家
  • AL類澱粉蛋白沉積症的市場規模:主要7個國家,各治療藥物

第14章 屬性分析

第15章 主要7個國家:市場未來展望

  • 美國的市場規模
    • AL類澱粉蛋白沉積症的整體市場規模
    • 市場規模:各治療藥物
  • 歐洲主要5個國家 (EU5) 市場:市場規模與未來展望
    • 德國的市場規模
    • 法國的市場規模
    • 義大利的市場規模
    • 西班牙的市場規模
    • 英國的市場規模
  • 日本市場:市場規模與未來展望

第16章 AL類澱粉蛋白沉積症的點閱存取醫療費償付:概要

第17章 產業的有學識者 (KOL)的見解

第18章 推動市場要素

第19章 市場阻礙因素

第20章 附錄

第21章 DelveInsight的服務內容

第22章 免責聲明

第23章 關於DelveInsight

目錄
Product Code: DIMI1060

DelveInsight's "AL Amyloidosis - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the AL Amyloidosis , historical and forecasted epidemiology as well as the AL Amyloidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The AL Amyloidosis market report provides current treatment practices, emerging drugs, AL Amyloidosis market share of the individual therapies, current and forecasted AL Amyloidosis market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current AL Amyloidosis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

AL Amyloidosis Disease Understanding and Treatment Algorithm

The DelveInsight AL Amyloidosis market report gives a thorough understanding of the AL Amyloidosis by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for AL Amyloidosis .

Treatment

It covers the details of conventional and current medical therapies available in the AL Amyloidosis market for the treatment of the condition. It also provides AL Amyloidosis treatment algorithms and guidelines in the United States, Europe, and Japan.

AL Amyloidosis Epidemiology

The AL Amyloidosis epidemiology division provide insights about historical and current AL Amyloidosis patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted AL Amyloidosis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- AL Amyloidosis Epidemiology

The epidemiology segment also provides the AL Amyloidosis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

AL Amyloidosis Drug Chapters

Drug chapter segment of the AL Amyloidosis report encloses the detailed analysis of AL Amyloidosis marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the AL Amyloidosis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for AL Amyloidosis treatment.

AL Amyloidosis Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for AL Amyloidosis treatment.

AL Amyloidosis Market Outlook

The AL Amyloidosis market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted AL Amyloidosis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of AL Amyloidosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, AL Amyloidosis market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the AL Amyloidosis market in 7MM.

The United States Market Outlook

This section provides the total AL Amyloidosis market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total AL Amyloidosis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total AL Amyloidosis market size and market size by therapies in Japan is also mentioned.

AL Amyloidosis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the AL Amyloidosis market or expected to get launched in the market during the study period 2017-2030. The analysis covers AL Amyloidosis market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

AL Amyloidosis Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses AL Amyloidosis key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for AL Amyloidosis emerging therapies.

Reimbursement Scenario in AL Amyloidosis

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in AL Amyloidosis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or AL Amyloidosis market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the AL Amyloidosis Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of AL Amyloidosis , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the AL Amyloidosis epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for AL Amyloidosis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of AL Amyloidosis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global AL Amyloidosis market

Report Highlights:

  • In the coming years, AL Amyloidosis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence AL Amyloidosis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for AL Amyloidosis . Launch of emerging therapies will significantly impact the AL Amyloidosis market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for AL Amyloidosis
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

AL Amyloidosis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • AL Amyloidosis Pipeline Analysis
  • AL Amyloidosis Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

AL Amyloidosis Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • AL Amyloidosis Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

AL Amyloidosis Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the AL Amyloidosis market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the AL Amyloidosis total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest AL Amyloidosis market size during the forecast period (2017-2030)?
  • At what CAGR, the AL Amyloidosis market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the AL Amyloidosis market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the AL Amyloidosis market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the AL Amyloidosis ?
  • What is the historical AL Amyloidosis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of AL Amyloidosis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to AL Amyloidosis ?
  • Out of all 7MM countries, which country would have the highest prevalent population of AL Amyloidosis during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the AL Amyloidosis treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of AL Amyloidosis in the USA, Europe, and Japan?
  • What are the AL Amyloidosis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of AL Amyloidosis ?
  • How many therapies are developed by each company for AL Amyloidosis treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for AL Amyloidosis treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the AL Amyloidosis therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for AL Amyloidosis and their status?
  • What are the key designations that have been granted for the emerging therapies for AL Amyloidosis ?
  • What are the global historical and forecasted market of AL Amyloidosis ?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the AL Amyloidosis market
  • To understand the future market competition in the AL Amyloidosis market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for AL Amyloidosis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for AL Amyloidosis market
  • To understand the future market competition in the AL Amyloidosis market

Table of Contents

1. Key Insights

2. Executive Summary of AL Amyloidosis

3. Competitive Intelligence Analysis for AL Amyloidosis

4. AL Amyloidosis : Market Overview at a Glance

  • 4.1. AL Amyloidosis Total Market Share (%) Distribution in 2017
  • 4.2. AL Amyloidosis Total Market Share (%) Distribution in 2030

5. AL Amyloidosis : Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. AL Amyloidosis Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. AL Amyloidosis Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. AL Amyloidosis Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. AL Amyloidosis Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. AL Amyloidosis Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. AL Amyloidosis Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. AL Amyloidosis Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. AL Amyloidosis Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. AL Amyloidosis Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. AL Amyloidosis Treatment and Management
  • 8.2. AL Amyloidosis Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of AL Amyloidosis Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. AL Amyloidosis : Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. AL Amyloidosis Market Size in 7MM
  • 13.3. AL Amyloidosis Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. AL Amyloidosis Total Market Size in the United States
    • 15.1.2. AL Amyloidosis Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. AL Amyloidosis Total Market Size in Germany
    • 15.3.2. AL Amyloidosis Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. AL Amyloidosis Total Market Size in France
    • 15.4.2. AL Amyloidosis Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. AL Amyloidosis Total Market Size in Italy
    • 15.5.2. AL Amyloidosis Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. AL Amyloidosis Total Market Size in Spain
    • 15.6.2. AL Amyloidosis Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. AL Amyloidosis Total Market Size in the United Kingdom
    • 15.7.2. AL Amyloidosis Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. AL Amyloidosis Total Market Size in Japan
    • 15.8.3. AL Amyloidosis Market Size by Therapies in Japan

16. Access and Reimbursement Overview of AL Amyloidosis

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.

List of Tables

  • Table 1: 7MM AL Amyloidosis Epidemiology (2017-2030)
  • Table 2: 7MM AL Amyloidosis Diagnosed and Treatable Cases (2017-2030)
  • Table 3: AL Amyloidosis Epidemiology in the United States (2017-2030)
  • Table 4: AL Amyloidosis Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5: AL Amyloidosis Epidemiology in Germany (2017-2030)
  • Table 6: AL Amyloidosis Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7: AL Amyloidosis Epidemiology in France (2017-2030)
  • Table 8: AL Amyloidosis Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9: AL Amyloidosis Epidemiology in Italy (2017-2030)
  • Table 10: AL Amyloidosis Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11: AL Amyloidosis Epidemiology in Spain (2017-2030)
  • Table 12: AL Amyloidosis Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13: AL Amyloidosis Epidemiology in the UK (2017-2030)
  • Table 14: AL Amyloidosis Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15: AL Amyloidosis Epidemiology in Japan (2017-2030)
  • Table 16: AL Amyloidosis Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17: Drug Name, Clinical Trials by Recruitment status
  • Table 18: Drug Name, Clinical Trials by Zone
  • Table 19: Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20: Region-wise Market Size in USD, Million (2017-2030)
  • Table 21: 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22: United States Market Size in USD, Million (2017-2030)
  • Table 23: United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24: Germany Market Size in USD, Million (2017-2030)
  • Table 25: Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26: France Market Size in USD, Million (2017-2030)
  • Table 27: France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28: Italy Market Size in USD, Million (2017-2030)
  • Table 29: Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30: Spain Market Size in USD, Million (2017-2030)
  • Table 31: Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32: United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33: United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34: Japan Market Size in USD, Million (2017-2030)
  • Table 35: Japan Market Size by Therapy in USD, Million (2017-2030)

The list of tables is not exhaustive; the final content may vary

List of Figures

  • Figure 1: 7MM AL Amyloidosis Epidemiology (2017-2030)
  • Figure 2: 7MM AL Amyloidosis Diagnosed and Treatable Cases (2017-2030)
  • Figure 3: AL Amyloidosis Epidemiology in the United States (2017-2030)
  • Figure 4: AL Amyloidosis Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5: AL Amyloidosis Epidemiology in Germany (2017-2030)
  • Figure 6: AL Amyloidosis Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7: AL Amyloidosis Epidemiology in France (2017-2030)
  • Figure 8: AL Amyloidosis Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9: AL Amyloidosis Epidemiology in Italy (2017-2030)
  • Figure 10: AL Amyloidosis Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11: AL Amyloidosis Epidemiology in Spain (2017-2030)
  • Figure 12: AL Amyloidosis Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13: AL Amyloidosis Epidemiology in the UK (2017-2030)
  • Figure 14: AL Amyloidosis Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15: AL Amyloidosis Epidemiology in Japan (2017-2030)
  • Figure 16: AL Amyloidosis Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17: Drug Name, Clinical Trials by Recruitment status
  • Figure 18: Drug Name, Clinical Trials by Zone
  • Figure 19: Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20: Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21: 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22: United States Market Size in USD, Million (2017-2030)
  • Figure 23: United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24: Germany Market Size in USD, Million (2017-2030)
  • Figure 25: Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26: France Market Size in USD, Million (2017-2030)
  • Figure 27: France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28: Italy Market Size in USD, Million (2017-2030)
  • Figure 29: Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30: Spain Market Size in USD, Million (2017-2030)
  • Figure 31: Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32: United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33: United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34: Japan Market Size in USD, Million (2017-2030)
  • Figure 35: Japan Market Size by Therapy in USD, Million (2017-2030)

The list of figures is not exhaustive; the final content may vary.